Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In SH, CpG island methylation frequencies of p16(INK4a) (0.0%) and RASSF1A (12.5%) were significantly lower than those in adenocarcinoma (29.4% and 38.2%, respectively); the frequencies of HOX D9, D11, and D13 gene methylation in SH were 37.5%, 33.3%, and 33.3%, respectively.
|
21649526 |
2011 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The p16 coding gene is often mutated in glioblastomas, pancreatic adenocarcinomas and melanoma-prone pedigrees, but, until recently, the significance of these allelic variants has remained unclear.
|
7566978 |
1995 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Here we demonstrate that exposure to plutonium may elevate the risk for adenocarcinoma through specifically targeting the p16 gene for inactivation by promoter methylation.
|
14742312 |
2004 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We determined the prevalence of allelic loss at 9p21 and mutations in CDKN2 in esophageal adenocarcinomas and investigated the order in which they occurred relative to the development of aneuploidy and cancer during neoplastic progression.
|
8934532 |
1996 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We determined whether alterations in the expression of p53, p16(INK4) and p21(WAF1/CIP1) influence the invasiveness of a subset of gastric adenocarcinomas co-expressing TGFalpha and EGFR.
|
15246559 |
2004 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Homozygous deletion of p16 appears to be common in esophageal squamous cell carcinomas but in adenocarcinomas, both gene deletion and transcriptional silencing of p16 were infrequent.
|
9333024 |
1997 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Synchronous lung cancers from 60 patients (42 with adenocarcinoma and 18 with squamous cell carcinoma), clinically considered to represent intrapulmonary metastases, were histologically subtyped according to the 2015 World Health Organization classification of lung tumors and subjected to genotypic analysis (KRAS, EGFR, BRAF, PIK3CA, ALK, MET and ROS1 in adenocarcinoma and PIK3CA and p16 in squamous cell carcinoma).
|
27080983 |
2016 |
Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
The prevalence of methylation for all genes was similar between adenocarcinomas from smokers and never smokers, although the prevalence for methylation of the p16 gene tended to be higher in smokers compared to never smokers.
|
15578700 |
2005 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
E6, p53 and p16 demonstrated significantly different expression levels in squamous epithelial tissue compared with adenocarcinomas.
|
29085443 |
2017 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our results showed two hypomethylated genes (CDKN2A and MGMT) and three hypermethylated genes (CDH13, RUNX3 and APC) in ACs compared with SCCs.
|
26862903 |
2016 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Methylation levels of the p16 promoter were significantly higher in squamous cell carcinoma than in adenocarcinoma (p = 0.020).
|
19795445 |
2010 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Stromal p16 expression was evaluated in endocervical adenocarcinomas, including usual-type endocervical adenocarcinoma (UEA), intestinal-type mucinous carcinoma (MC-I), and MC-G.
|
29848709 |
2018 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The hypermethylation of p16 INK4A and MGMT genes in the uterine cervix may indicate the presence of malignant cells, and p16 INK4A immunostaining is useful in grading CIN and diagnosing invasive SCC and adenocarcinoma.
|
15785933 |
2005 |
Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
P14ARF was methylated in 3 of 15 (20%) adenocarcinomas.
|
15185075 |
2004 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In the rat, 94% of adenocarcinomas induced by the tobacco specific carcinogen 4-methylnitrosamino-1-(3-pyridyl)-1-butanone were hypermethylated at the p16 gene promoter; most important, this methylation change was frequently detected in precursor lesions to the tumors: adenomas, and hyperplastic lesions.
|
9751761 |
1998 |
Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Fourteen of 15 (93.3%) invasive pancreatic ductal adenocarcinomas showed methylation of the ppENK gene and 4 of 15 (26.7%) showed methylation of the p16 gene.
|
12000709 |
2002 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Our data suggest a role for CDKN2A/B and FHIT in early progression of BE to dysplasia and adenocarcinoma that warrants future mechanistic research.
|
31001805 |
2019 |
Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
CpG methylation as well as histone H3 methylation of lysines 9 and 27 contribute independently to ARF gene silencing in adenocarcinoma cell lines and can be reversed by 5-aza-2'-deoxycytidine.
|
18410530 |
2009 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We found that 34% of NSCLC patients had aberrant P14ARF protein expression, which was more frequent in adenocarcinomas (AD; 44%) than in squamous cell carcinomas (22%; P = 0.024).
|
15269146 |
2004 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
To cast light on the contribution of methylation to genesis of ulcerative colitis (UC)-associated tumors, promoter methylation and expression of O6-methylguanine DNA methyltransferase (MGMT), hMLH1, p16INK4, and E-cadherin were examined in 14 low-grade dysplasias (LGDs), 15 high-grade dysplasias (HGDs), and 14 adenocarcinomas associated with UC and, for comparison, in 30 sporadic adenomas with LGD, 30 adenomas with HGD, and 60 adenocarcinomas, using methylation-specific polymerase chain reaction and immunohistochemical analysis.
|
17276933 |
2007 |
Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
The prevalence of p16 methylation was greater in squamous cell carcinoma (41%) compared with adenocarcinoma (22%; P = 0.03; Fisher's exact test).
|
11309302 |
2001 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Previously described genomic alterations in esophageal adenocarcinomas could be confirmed by SNP microarrays, such as amplification on 8q (CMYC, confirmed by FISH) and 20q13 or deletion/LOH on 3p (FHIT) and 9p (CDKN2A).
|
18663352 |
2009 |
Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
In multivariate analysis, p16 hypermethylation was more prevalent in lung tumours from male than female patients (P = 0.018) and in squamous cell carcinomas than in adenocarcinomas (P = 0.025).
|
22217548 |
2012 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The immunohistochemical expression pattern of p16 in biopsy samples has been useful as part of a panel to distinguish adenocarcinomas arising from the endometrium from those arising from the endocervix.
|
17581420 |
2007 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
No mutations in exon 2 of CDKN2 were found in 20 stomach adenocarcinomas.
|
9873831 |
1998 |